Liquidation: John Hancock Funds II

Form Type: 497

Filing Date: 2025-03-27

Corporate Action: Liquidation

Type: New

Accession Number: 000119312525065486

Filing Summary: On March 24-27, 2025, the Board of Trustees of John Hancock Funds II approved the liquidation of the International Small Company Fund, determining that its continuation was not in the best interests of the fund or its shareholders. Effective April 28, 2025, the fund will cease to accept orders for new shares, while existing shareholders can continue to make their investments until the liquidation. The plan will see all assets distributed pro rata to shareholders, with a liquidation date set for July 18, 2025, at which point all outstanding shares will be cancelled. This follows specific IRS designations for tax reporting regarding capital gains.

Document Link: View Document

Form Type: 497K

Filing Date: 2025-03-27

Corporate Action: Liquidation

Type: New

Accession Number: 000119312525065490

Filing Summary: On March 27, 2025, John Hancock Funds II announced the closing and liquidation of the International Small Company Fund following a meeting of the Board of Trustees held from March 24 to 27, 2025. The Board determined that continuing the fund was not in the best interest of shareholders due to adverse factors affecting its operations and ability to conduct business viably. The fund will stop accepting purchase orders from April 28, 2025, though some specific accounts may still access shares. The liquidation of the fund is scheduled for July 18, 2025, when all assets will be distributed to shareholders and outstanding shares will be redeemed and canceled.

Document Link: View Document

Form Type: 497

Filing Date: 2025-02-05

Corporate Action: Liquidation

Type: New

Accession Number: 000119312525020466

Filing Summary: Effective March 24, 2025, Ziad Bakri, the portfolio manager of the John Hancock Funds II Health Sciences Fund, will be on sabbatical and Jason Nogueira will take over as the interim portfolio manager. Jason Nogueira is responsible for the day-to-day management of the fund's portfolio until its planned liquidation on or about March 28, 2025. The document amends and restates information regarding the portfolio management and details related to Nogueira's background, confirming his management of the fund since the Effective Date.

Document Link: View Document

Form Type: 497

Filing Date: 2025-01-23

Corporate Action: Liquidation

Type: New

Accession Number: 000119312525011448

Filing Summary: The Board of Trustees of John Hancock Funds II has approved the closing and liquidation of the Fundamental Global Franchise Fund, Health Sciences Fund, and Science & Technology Fund due to adverse factors affecting the funds' ability to operate viably. The funds will stop accepting purchase orders around February 24, 2025, with certain exceptions for specific advisory programs and retirement accounts. On March 28, 2025, all assets will be distributed pro rata to shareholders, and outstanding shares will be redeemed and canceled. The continuation of these funds is deemed not in the best interest of the shareholders.

Document Link: View Document

Form Type: 497K

Filing Date: 2025-01-23

Corporate Action: Liquidation

Type: New

Accession Number: 000119312525011450

Filing Summary: The Board of Trustees of John Hancock Funds II has approved the closing and liquidation of the Fundamental Global Franchise Fund. This decision was made as the Board determined that continuing the fund is not in the best interests of the fund or its shareholders due to various factors adversely affecting the fund's ability to operate economically. The fund will stop accepting orders for share purchases starting on or about February 24, 2025, although certain programs may still access shares. On or about March 28, 2025, the fund will distribute all its assets to shareholders, ensuring that all outstanding shares will be redeemed and cancelled by the end of that day.

Document Link: View Document